Conversely, the potential benefit of prospective identification of DPYD mutations is that, careful monitoring and gradual dose escalation, may allow patients with DPD deficiency to receive fluoropyrimidine chemotherapy safely[6,105]. The gene discussed is DPYD; the disease is hyperinsulinemic hypoglycemia, familial, 4.